Certificate Pursuant to Regulation 74(5) of the SEBI (DP) Reg, 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has submitted a routine compliance certificate to BSE from its Registrar and Share Transfer Agent (Purva Sharegistry India Pvt. Ltd.) for the quarter ended March 31, 2025. The RTA confirms that any share certificates received for dematerialization during the quarter were processed, verified, and cancelled, with the depository's name substituted as the registered owner in the company's records. The attached schedule shows NIL share certificates were dematerialized between January 1, 2025 and March 31, 2025, meaning no shareholders converted physical shares to demat form during the quarter. The filing is signed by Managing Director Fredun Nariman Medhora and was submitted to BSE on April 15, 2025.
This is a routine quarterly regulatory compliance filing with no business or financial impact. It simply confirms that the RTA followed proper procedure for handling dematerialization requests (none this quarter) and does not affect share price, dividends, or shareholder value.